A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer.
Forty-one patients with advanced breast cancer were given carboplatin and vinorelbine as second-line therapy. Overall objective response rate was 46% (95% confidence interval 26-56%). Myelotoxicity was the most frequently observed toxic effect; grade III-IV leucopenia occurred in 46% of the patients. Our regimen is active as second-line chemotherapy for advanced breast cancer and warrants further evaluation.
Iaffaioli
R V
RV
Istituto di Medicina Interna, Università di Cagliari, Italy.
Tortoriello
A
A
Facchini
G
G
Santangelo
M
M
De Sena
G
G
Gesue
G
G
Bucci
L
L
Scaramellino
G
G
Anastasio
E
E
Finizio
A
A
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D009362:Neoplasm Metastasis; D010689:Phlebitis / Q000139:chemically induced; D012074:Remission Induction; D016879:Salvage Therapy; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D000077235:Vinorelbine
D016179:Granulocyte Colony-Stimulating Factor; D014747:Vinblastine; D016190:Carboplatin; D000077235:Vinorelbine